See more : Global Energy Metals Corporation (GBLEF) Income Statement Analysis – Financial Results
Complete financial analysis of AmerisourceBergen Corporation (ABC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AmerisourceBergen Corporation, a leading company in the Medical – Distribution industry within the Healthcare sector.
- Apple Inc. (AAPL.MX) Income Statement Analysis – Financial Results
- BELLSYSTEM24 Holdings, Inc. (6183.T) Income Statement Analysis – Financial Results
- Agios Pharmaceuticals, Inc. (AGIO) Income Statement Analysis – Financial Results
- Hellenic Telecommunications Organization S.A. (HLTOY) Income Statement Analysis – Financial Results
- Pegasus Hava Tasimaciligi Anonim Sirketi (PGSUS.IS) Income Statement Analysis – Financial Results
AmerisourceBergen Corporation (ABC)
About AmerisourceBergen Corporation
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 262.17B | 238.59B | 213.99B | 189.89B | 179.59B | 167.94B | 153.14B | 146.85B | 135.96B | 119.57B | 87.96B | 79.49B | 80.22B | 77.95B | 71.76B | 70.19B | 66.07B | 61.20B | 54.58B | 53.18B | 49.66B | 45.23B | 16.19B | 11.65B | 9.81B | 8.67B | 7.82B | 5.55B | 4.67B | 4.30B |
Cost of Revenue | 253.21B | 230.29B | 207.05B | 184.70B | 174.45B | 163.33B | 148.60B | 142.58B | 132.43B | 116.59B | 85.45B | 76.82B | 77.68B | 75.60B | 69.66B | 68.14B | 63.75B | 58.97B | 52.60B | 51.00B | 47.41B | 43.21B | 15.49B | 11.12B | 9.33B | 8.25B | 7.43B | 5.25B | 4.40B | 4.06B |
Gross Profit | 8.96B | 8.30B | 6.94B | 5.19B | 5.14B | 4.61B | 4.55B | 4.27B | 3.53B | 2.98B | 2.51B | 2.67B | 2.54B | 2.36B | 2.10B | 2.05B | 2.33B | 2.23B | 1.98B | 2.18B | 2.25B | 2.02B | 700.12M | 520.89M | 475.60M | 423.10M | 389.30M | 304.90M | 268.80M | 243.30M |
Gross Profit Ratio | 3.42% | 3.48% | 3.24% | 2.73% | 2.86% | 2.75% | 2.97% | 2.91% | 2.60% | 2.49% | 2.85% | 3.36% | 3.17% | 3.02% | 2.93% | 2.92% | 3.52% | 3.65% | 3.63% | 4.10% | 4.53% | 4.48% | 4.32% | 4.47% | 4.85% | 4.88% | 4.98% | 5.49% | 5.76% | 5.66% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -58.48M | 888.84M | 958.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 2.66B | 2.46B | 2.13B | 2.09B | 1.92B | 1.59B | 1.33B | 1.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.32B | 324.14M | 334.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 5.31B | 4.85B | 3.59B | 2.77B | 2.66B | 2.46B | 2.13B | 2.09B | 1.92B | 1.59B | 1.33B | 1.23B | 1.20B | 1.16B | 1.13B | 1.12B | 1.41B | 1.40B | 1.26B | 1.21B | 1.29B | 1.22B | 408.76M | 303.04M | 281.80M | 254.90M | 255.40M | 195.40M | 160.90M | 150.70M |
Other Expenses | 1.31B | 693.90M | 505.17M | 391.06M | 462.41M | -25.47M | 2.73M | 5.05M | -13.60M | 4.36M | -44.00K | 5.83M | 0.00 | 0.00 | 1.43B | 1.43B | 1.51B | 1.48B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 6.62B | 5.54B | 4.10B | 3.16B | 3.13B | 2.93B | 2.53B | 2.46B | 2.16B | 1.77B | 1.50B | 1.37B | 1.33B | 1.25B | 1.20B | 1.21B | 1.50B | 1.48B | 1.34B | 1.29B | 1.36B | 1.28B | 427.63M | 320.46M | 301.70M | 271.50M | 269.70M | 207.00M | 171.00M | 165.40M |
Cost & Expenses | 259.83B | 235.83B | 211.15B | 187.86B | 177.58B | 166.25B | 151.12B | 145.03B | 134.59B | 118.36B | 86.95B | 78.19B | 79.01B | 76.85B | 70.86B | 69.35B | 65.25B | 60.45B | 53.94B | 52.29B | 48.77B | 44.49B | 15.92B | 11.44B | 9.63B | 8.52B | 7.70B | 5.45B | 4.57B | 4.22B |
Interest Income | 0.00 | 21.31M | 8.47M | 20.64M | 37.71M | 14.94M | 3.86M | 4.44M | 2.99M | 841.00K | 1.15M | 1.80M | 2.18M | 2.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 228.93M | 210.67M | 182.54M | 137.88M | 157.77M | 174.70M | 145.19M | 139.91M | 99.00M | 76.86M | 73.90M | 95.42M | 78.90M | 72.49M | 58.31M | 32.24M | 32.29M | 12.46M | 0.00 | 0.00 | 0.00 | 140.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 963.90M | 1.11B | 1.05B | 391.06M | 462.41M | 465.13M | 397.60M | 364.74M | 243.28M | 185.29M | 162.19M | 141.05M | 108.31M | 86.46M | 78.91M | 95.88M | 104.34M | 96.93M | 90.88M | 87.09M | 80.44M | 66.58M | 24.71M | 17.42M | 19.90M | 16.60M | 14.30M | 11.60M | 10.10M | 14.70M |
EBITDA | 3.37B | 3.47B | 3.41B | 2.43B | 2.49B | 2.08B | 2.42B | 2.19B | 1.60B | 1.40B | 1.17B | 1.45B | 1.32B | 1.19B | 974.43M | 950.52M | 931.83M | 841.25M | 843.99M | 994.88M | 967.77M | 833.49M | 307.59M | 216.73M | 208.70M | 194.90M | 133.90M | 109.50M | 107.90M | 272.40M |
EBITDA Ratio | 1.28% | 1.46% | 1.59% | 1.28% | 1.39% | 1.24% | 1.58% | 1.49% | 1.18% | 1.17% | 1.33% | 1.82% | 1.64% | 1.53% | 1.36% | 1.35% | 1.41% | 1.37% | 1.55% | 1.87% | 1.95% | 1.84% | 1.90% | 1.86% | 2.13% | 2.25% | 1.71% | 1.97% | 2.31% | 6.33% |
Operating Income | 2.34B | 2.37B | 2.35B | 2.04B | 2.03B | 1.44B | 1.11B | 1.53B | 417.37M | 778.88M | 898.40M | 1.25B | 1.20B | 1.10B | 883.75M | 827.86M | 820.34M | 748.71M | 636.95M | 890.43M | 883.11M | 718.43M | 259.38M | 200.43M | 173.90M | 151.60M | 119.60M | 97.90M | 97.80M | 77.90M |
Operating Income Ratio | 0.89% | 0.99% | 1.10% | 1.07% | 1.13% | 0.86% | 0.73% | 1.04% | 0.31% | 0.65% | 1.02% | 1.58% | 1.50% | 1.42% | 1.23% | 1.18% | 1.24% | 1.22% | 1.17% | 1.67% | 1.78% | 1.59% | 1.60% | 1.72% | 1.77% | 1.75% | 1.53% | 1.76% | 2.09% | 1.81% |
Total Other Income/Expenses | -179.90M | -183.32M | -132.34M | -7.33B | -1.06B | -266.26M | -92.46M | -134.86M | -143.22M | -105.46M | -73.94M | -89.60M | -72.10M | -75.87M | -59.68M | -66.52M | -35.29M | -8.08M | -168.12M | -130.06M | -156.98M | -146.38M | -56.54M | -40.73M | -54.60M | -68.80M | -41.60M | -35.90M | -52.30M | -242.50M |
Income Before Tax | 2.16B | 2.18B | 2.22B | -5.29B | 967.11M | 1.18B | 967.89M | 1.39B | 274.15M | 673.43M | 824.46M | 1.16B | 1.13B | 1.03B | 824.07M | 761.34M | 785.05M | 740.63M | 468.83M | 760.37M | 726.13M | 572.05M | 202.83M | 159.70M | 119.30M | 82.80M | 78.00M | 62.00M | 45.50M | -164.60M |
Income Before Tax Ratio | 0.82% | 0.91% | 1.04% | -2.79% | 0.54% | 0.70% | 0.63% | 0.95% | 0.20% | 0.56% | 0.94% | 1.46% | 1.41% | 1.32% | 1.15% | 1.08% | 1.19% | 1.21% | 0.86% | 1.43% | 1.46% | 1.26% | 1.25% | 1.37% | 1.22% | 0.96% | 1.00% | 1.12% | 0.97% | -3.83% |
Income Tax Expense | 428.26M | 516.52M | 677.25M | -1.89B | 112.97M | -438.47M | 553.40M | -37.02M | 409.04M | 389.40M | 331.02M | 454.95M | 424.02M | 391.02M | 312.22M | 292.27M | 291.28M | 272.62M | 176.90M | 291.98M | 284.90M | 227.11M | 77.73M | 60.69M | 48.40M | 32.30M | 30.60M | 19.30M | 17.30M | 7.80M |
Net Income | 1.75B | 1.70B | 1.54B | -3.40B | 855.37M | 1.66B | 414.48M | 1.43B | -134.89M | 276.48M | 433.71M | 718.99M | 706.62M | 636.75M | 503.40M | 250.56M | 469.17M | 467.71M | 319.20M | 468.39M | 441.23M | 344.94M | 125.10M | 99.01M | 67.50M | 50.50M | 45.40M | 35.50M | 10.20M | -207.70M |
Net Income Ratio | 0.67% | 0.71% | 0.72% | -1.79% | 0.48% | 0.99% | 0.27% | 0.97% | -0.10% | 0.23% | 0.49% | 0.90% | 0.88% | 0.82% | 0.70% | 0.36% | 0.71% | 0.76% | 0.58% | 0.88% | 0.89% | 0.76% | 0.77% | 0.85% | 0.69% | 0.58% | 0.58% | 0.64% | 0.22% | -4.83% |
EPS | 8.53 | 8.15 | 7.48 | -16.60 | 4.07 | 7.53 | 1.90 | 6.73 | -0.62 | 1.22 | 1.88 | 2.84 | 2.59 | 2.26 | 1.67 | 0.78 | 1.27 | 1.14 | 0.75 | 1.05 | 1.01 | 0.82 | 0.55 | 0.48 | 0.33 | 0.26 | 0.23 | 0.20 | 0.07 | -5.19 |
EPS Diluted | 8.53 | 8.04 | 7.39 | -16.60 | 4.04 | 7.53 | 1.87 | 6.32 | -0.62 | 1.17 | 1.84 | 2.80 | 2.54 | 2.22 | 1.66 | 0.77 | 1.25 | 1.13 | 0.74 | 0.99 | 0.95 | 0.77 | 0.50 | 0.48 | 0.33 | 0.25 | 0.23 | 0.19 | 0.07 | -5.19 |
Weighted Avg Shares Out | 204.59M | 208.47M | 205.92M | 204.78M | 210.17M | 217.87M | 218.38M | 212.21M | 217.79M | 227.37M | 231.07M | 252.91M | 272.47M | 282.26M | 300.57M | 321.28M | 370.36M | 410.02M | 425.26M | 447.35M | 435.38M | 419.74M | 228.74M | 206.21M | 202.79M | 190.71M | 198.35M | 182.05M | 145.71M | 40.00M |
Weighted Avg Shares Out (Dil) | 204.59M | 211.21M | 208.47M | 204.78M | 211.84M | 220.34M | 221.60M | 225.96M | 217.79M | 235.41M | 235.35M | 256.90M | 277.72M | 287.25M | 302.75M | 324.92M | 375.77M | 414.89M | 431.08M | 471.12M | 463.82M | 448.91M | 251.23M | 208.08M | 206.73M | 202.85M | 200.42M | 184.42M | 145.71M | 40.00M |
Are Investors Undervaluing AmerisourceBergen (ABC) Right Now?
Dividend Champion, Contender, And Challenger Highlights: Week Of February 19
5 Stocks to Keep an Eye on Following Upgrade by Brokers
Is This Warren Buffett Stock a Buy for Dividend Growth Investors?
AmerisourceBergen Releases 2022 ESG Summary Report to Share Progress and Impact on Environmental, Social and Governance Priorities
Should Value Investors Buy AmerisourceBergen (ABC) Stock?
Dividend Champion, Contender, And Challenger Highlights: Week Of February 5
Here's Why AmerisourceBergen (ABC) is a Strong Value Stock
5 Dental Supplies Stocks to Buy Amid Recovering Prospects
AmerisourceBergen (ABC) Q1 Earnings Top, EPS View Raised
Source: https://incomestatements.info
Category: Stock Reports